Side effects were similar between patients who got the drug and those in a testing group who received a dummy pill. The results were so strong that independent medical experts monitoring the trial recommended stopping it early. The company reported earlier this month that the pill cut hospitalizations and deaths by half among patients with early symptoms of COVID-19. “I think it’s a very powerful tool to add to the toolbox.” Nicholas Kartsonis, a senior vice president with Merck’s infectious disease unit. “The value here is that it’s a pill so you don’t have to deal with the infusion centers and all the factors around that,” said Dr.
That is roughly the way COVID-19 infusion drugs are used. Merck and its partner Ridgeback Biotherapeutic said they specifically asked the agency to grant emergency use for adults with mild-to-moderate COVID-19 who are at risk for severe disease or hospitalization.
0 kommentar(er)
